Overview

Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients

Status:
Terminated
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the association of ZMP is safe and provides benefits in patients with relapsed/refractory MM.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Tiziana Marangon
Treatments:
Melphalan
Prednisone
Vorinostat